Organogenesis Holdings Inc. cash flow statement
In fiscal 2025, Organogenesis Holdings Inc.'s operations generated −$10.3m of cash; it spent $14.2m on capital projects, leaving free cash flow of −$24.5m.
Cash flow statement
| Fiscal year | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | −5 | −3 | −61 | −34 | 5 | 62 | 25 | 31 | 14 | −10 | 32 |
| Depreciation and amortisation | 6 | 4 | 3 | 4 | 4 | 6 | 6 | 10 | 14 | 15 | 16 |
| Stock-based pay | 0 | 1 | 1 | 1 | 2 | 4 | 7 | 9 | 11 | 13 | 14 |
| Capital spending | 1 | 2 | 2 | 6 | 18 | 31 | 34 | 24 | 10 | 14 | 11 |
| Free cash flow | −6 | −6 | −62 | −40 | −12 | 31 | −9 | 7 | 4 | −24 | 21 |
| Free cash flow after stock pay | −7 | −7 | −64 | −40 | −14 | 27 | −16 | −2 | −6 | −38 | 7 |
| Share buybacks | — | — | — | — | — | — | 0 | 0 | 25 | — | — |
| Shares issued | 304 | — | 92 | 50 | 65 | — | — | — | — | — | — |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 9 | 11 | −20 | −33 | 3 | 39 | 21 | −32 |
| Depreciation and amortisation | 4 | 4 | 3 | 4 | 4 | 4 | 4 | 4 |
| Stock-based pay | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 3 |
| Capital spending | 3 | 3 | 4 | 4 | 2 | 5 | 3 | 1 |
| Free cash flow | 6 | 8 | −24 | −37 | 1 | 35 | 18 | −33 |
| Free cash flow after stock pay | 3 | 5 | −27 | −39 | −2 | 30 | 14 | −36 |
Compare with peers
- UFP Technologies Inc cash flow
- Mimedx Group, Inc. cash flow
- Embecta Corp. cash flow
- Orasure Technologies Inc cash flow
- ICU Medical Inc cash flow
Head to head: ORGO vs UFPTMDXG vs ORGOEMBC vs ORGOORGO vs OSUR
More: Health Care Supplies stocks compared, Health Care sector, rankings of US companies